Management of Post-Facelift Facial Paralysis With Botulinum Toxin Type A
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
REMIGIO, Adelina Fatima do Nascimento
ANDRADE, Antonio Carlos Herrmann de
Citação
AESTHETIC SURGERY JOURNAL, v.42, n.3, p.NP144-NP150, 2022
Resumo
Background Facial nerve injury after facelift is rare; hence, its treatment is poorly established. Botulinum toxin type A (BTXA) can be employed to resolve the asymmetry. To our knowledge, there is no protocol in the literature about the best timing for this treatment, injection sites, or recommended dose. Objectives The authors sought to propose a protocol to guide the management of asymmetries post-facelift. Methods Fifteen patients with post-rhytidectomy facial palsies were treated in the non-paralyzed side with BTXA. After analysis of the smile deviation vectors, it is possible to identify the muscles that should be treated. The dose varied from 1 to 2 volume-unit per point. Patients were examined after 15 days for outcomes evaluation and touch-up if needed. Patients were re-treated after 5 to 6 months in case of asymmetry recurrence. Results Symmetry was achieved in all cases. Six patients had definitive nerve lesions and required treatment every 6 months after the first session. Five patients had lesions affecting the upper third of the face; 4 of them were definitive nerve lesions. Two of the 4 patients who were treated less than 2 weeks after surgery recovered early from the post-facelift paralysis and developed reversed asymmetry due to the BTXA. In 7 patients, the post-facelift asymmetry was due to neuropraxis: the recovery from the nerve injury and BTXA treatment occurred symmetrically on both sides of the face in the following months after 1 single session. Conclusions Asymmetries post-facelift were successfully managed with the proposed protocol. The best time for injection was 2 to 4 weeks after surgery.
Palavras-chave
Referências
- BAKER DC, 1979, PLAST RECONSTR SURG, V64, P781, DOI 10.1097/00006534-197912000-00005
- Bloom JD, 2012, FACIAL PLAST SURG, V28, P260, DOI 10.1055/s-0032-1312703
- Chaffoo RAK, 2013, FACIAL PLAST SURG CL, V21, P551, DOI 10.1016/j.fsc.2013.07.007
- Cristel RT, 2019, FACIAL PLAST SURG CL, V27, P519, DOI 10.1016/j.fsc.2019.07.008
- Remigio AFD, 2015, PLAST RECONSTR SURG, V135, P239, DOI 10.1097/PRS.0000000000000800
- Guntinas-Lichius O, 2011, NEUROREHAB NEURAL RE, V25, P15, DOI 10.1177/1545968310376058
- Hwang K, 2014, J CRANIOFAC SURG, V25, P1476, DOI 10.1097/SCS.0000000000000577
- Lima W, 2018, PLAST RECONSTR SURG, V142, P1511, DOI 10.1097/PRS.0000000000004981
- Matarasso A, 2000, PLAST RECONSTR SURG, V106, P1185, DOI 10.1097/00006534-200010000-00033
- Peeva GP, 2006, EUR J NEUROSCI, V24, P2152, DOI 10.1111/j.1460-9568.2006.05091.x
- Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694
- Roostaeian J, 2015, PLAST RECONSTR SURG, V135, P1318, DOI 10.1097/PRS.0000000000001244
- Salles AG, 2015, PLAST RECONSTR SURG, V136, P1289, DOI 10.1097/PRS.0000000000001802
- Salles AG, 2009, AESTHET PLAST SURG, V33, P582, DOI 10.1007/s00266-009-9337-9
- Wittenberg GF, 2009, CURR OPIN NEUROL, V22, P582, DOI 10.1097/WCO.0b013e3283320229